Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-TKI”

276 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 276 results

Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Large-scale testing (Phase 3)Looking for participantsNCT05852990
What this trial is testing

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Instituto Nacional de Cancerologia de Mexico 28
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Large-scale testing (Phase 3)UnknownNCT03924050
What this trial is testing

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 440
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Large-scale testing (Phase 3)Looking for participantsNCT07155187
What this trial is testing

Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 430
Testing effectiveness (Phase 2)UnknownNCT03797391
What this trial is testing

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Who this might be right for
NeoplasmsNeoplasm MetastasisNon-Small-Cell Lung Cancer
Shanghai EpimAb Biotherapeutics Co., Ltd. 186
Testing effectiveness (Phase 2)UnknownNCT04982900
What this trial is testing

Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

Who this might be right for
Multiple Primary Lung Cancers
Ruijin Hospital 138
Not applicableNot Yet RecruitingNCT07338396
What this trial is testing

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients

Who this might be right for
Non Small Cell Lung Cancer NSCLC
Guangzhou University of Traditional Chinese Medicine 3,000
Testing effectiveness (Phase 2)UnknownNCT02811354
What this trial is testing

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

Who this might be right for
Carcinoma, Non-Small-Cell Lung
National University Hospital, Singapore 108
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193160
What this trial is testing

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Fudan University 45
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Testing effectiveness (Phase 2)UnknownNCT03002844
What this trial is testing

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Who this might be right for
Nonsmall Cell Lung CancerEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05601973
What this trial is testing

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 60
Testing effectiveness (Phase 2)UnknownNCT01861223
What this trial is testing

Afatinib Plus Nimotuzumb for NSCLC

Who this might be right for
NSCLC
Samsung Medical Center 50
Testing effectiveness (Phase 2)UnknownNCT02037997
What this trial is testing

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Fudan University 80
Not applicableStudy completedNCT00836160
What this trial is testing

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

Who this might be right for
Cancer
AstraZeneca 36
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Load More Results